Infection risks for patients w/MS treated w/Gilenya, Tysabri, Rituxan, injectable therapies on: February 11, 2020, 08:05:28 pm #1 From JAMA Neurology (February 2020; first published October 2019), "Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies." The researchers found that the beta interferons and Copaxone (glatiramer acetate) had the lowest infection rate, and rituximab had the highest.http://bit.ly/2SmaGeN Last Edit: February 11, 2020, 08:07:03 pm by agate Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
